Podimetrics, an organization that helps sufferers with diabetes stop severe problems, is teaming up with HealthMed, an worker well being and wellness platform.
HealthMed goals to combine Podimetrics’ SmartMat expertise into its portfolio of advantages supposed for big employers, hospitals and municipalities. The corporate additionally gives worker wellness and psychological well being applications.
Podimetrics’ SmartMat measures the foot temperature of high-risk sufferers and scans for early indicators of irritation that would result in wounds, amputations and diabetic foot ulcers.
“Our partnership with HealthMed is a powerful collaboration, and we’re excited to work collectively to assist people with complicated diabetes who’re on the biggest danger for severe problems,” Dr. Jon Bloom, CEO of Podimetrics, mentioned in a press release.
“We share a typical mission to give attention to prevention and enhance well being outcomes. This collaboration is aimed toward attaining that purpose collectively.”
Tracy Webster, founding father of HealthMed, mentioned the partnership with Podimetrics and its modern answer for managing difficult diabetes will profit self-insured employers and enhance the continuum of care.
“We stay up for the constructive influence we will make on well being outcomes and the general value of care,” Webster mentioned in a press release.
THE LARGER TREND
In March, Podimetrics partnered with profit administration group Alivi Well being, which integrated SmartMat expertise into its portfolio of specialty advantages to bolster its podiatry advantages for well being plans and payers.
In 2024, Podimetrics sued Eire-based Bluedrop Medical for patent infringement. Bluedrop has a tool that permits an individual with diabetes to scan their toes for potential cases of foot ulcers.
In line with the compliant, Bluedrop allegedly “straight and/or by way of subsidiaries, workers, intermediaries or commerce names” dedicated acts of infringement by “importing, providing to promote and promoting an instrumentality that infringes [Podimetrics’] Patents-in-Go well with.” The case was dismissed after Podmetrics withdrew its declare.
In 2022, Podimetrics scored $45 million in a Sequence C financing spherical. The capital was used to develop Podimetrics’ product growth and analysis groups in addition to improve the variety of providers supplied by its nurse assist groups.
In 2019, Podimetrics raised $13.4 million in Sequence B funding. Rock Well being, Norwich Ventures and Scientific Well being Improvement participated within the spherical.
Different corporations within the diabetes house embrace Dexcom, which in 2024 made a $75 million strategic funding in health-tracking ring maker Oura and established a strategic partnership to allow two-way information movement between Dexcom’s steady glucose monitor (CGM) and the Oura Ring. Dexcom’s $75 million funding introduced Oura’s valuation to greater than $5 billion.
Diabetes and insulin administration software program firm Glytec and pharmaceutical agency Roche joined forces final yr to permit the usage of Glytec’s software program in reference to Roche’s point-of-care smart-device hospital blood glucose system cobas pulse within the U.S. and international markets.
In line with Roche, cobas pulse’s strip structure gives lab-like outcomes and lowers the necessity to repeat checks. The system can be utilized on all affected person populations, together with neonates and intensive care sufferers.
